目的探讨脑立清胶囊联合培哚普利吲达帕胺片治疗老年原发性高血压的疗效观察。方法选取2018年4月-2020年4月在青岛市第九人民医院内科住院治疗的124例老年原发性高血压患者，根据治疗方法将124例老年原发性高血压患者分为对照组（62例）和观察组（62例）。对照组患者口服培哚普利吲达帕胺片，1片/次，1次/d。观察组患者在对照组的基础上给予口服脑立清胶囊，3粒/次，2次/d。两组连续服用7 d。观察两组患者的临床疗效，同时比较两组治疗前后的临床症状缓解时间、血压水平以及血清白细胞介素1（IL-1）、肿瘤坏死因子α（TNF-α）、高敏C反应蛋白（hs-CRP）、同型半胱氨酸（Hcy）、血管内皮素（ET-1）水平。结果治疗后，观察组临床总有效率为98.39%，显著高于对照组的85.48%（P<0.05）。治疗后，观察组患者的临床症状头痛、眩晕、胸闷、心悸缓解时间均短于对照组（P<0.05）。治疗后，两组收缩压（SBP）、舒张压（DBP）水平均显著降低，观察组患者SBP、DBP水平显著低于对照组（P<0.05）。治疗后，两组IL-1、hs-CR、TNF-α、Hcy、ET-1水平均显著降低（P<0.05）；且观察组患者血清因子水平均低于对照组（P<0.05）。结论脑立清胶囊与培哚普利吲达帕胺片联合治疗老年原发性高血压，临床效果较为显著，能够对患者的血压有明显改善，不良反应率低，安全可靠，值得在临床推广。

Objective To investigate the efficacy of Naoliqing Capsules combined with Perindopril and Indapamide Tablets in treatment of senile essential hypertension. Methods A total of 124 elderly patients with essential hypertension who were hospitalized in the Department of Internal Medicine of Qingdao Ninth People's Hospital from April 2018 to April 2020 were selected. According to the treatment methods, the 124 elderly patients with essential hypertension were divided into control group (62 cases) and observation group (62 cases). Patients in the control group were po administered with Perindopril and Indapamide Tablets, 1 tablet/time, once daily. Patients in the observation group were po administered with Naoliqing Capsules on the basis of control group, 3 grains/time, twice daily. Both groups were treated for 7 days. The clinical efficacy of two groups was observed, and the clinical symptom remission time, blood pressure, serum levels of IL-1, TNF-α, hs-CRP, Hcy, and ET-1 before and after treatment were compared between two groups. Results After treatment, the total clinical effective rate of observation group was 98.39%, which was significantly higher than 85.48% of control group (P < 0.05). After treatment, the relief time of clinical symptoms such as headache, vertigo, chest tightness, and palpitation in the observation group was shorter than that in the control group (P < 0.05). After treatment, the SBP and DBP levels in two groups were significantly decreased, and the SBP and DBP levels in observation group were significantly lower than control group (P < 0.05). After treatment, the levels of IL-1, hs-CRP, TNF-α, Hcy, and ET-1 in two groups were significantly decreased (P < 0.05), and serum factor levels in observation group were lower than those in control group (P < 0.05). Conclusion Naoliqing Capsules combined with Perindopril and Indapamide Tablets in treatment of elderly patients with essential hypertension has a significant clinical effect, can significantly improve the patient's blood pressure, low adverse reaction rate, safe and reliable, worthy of clinical promotion.

R972